Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine added to standard induction chemotherapy for untreated AML or high-risk RAEB
NL-OMON22750Phase 3Not yet recruiting
- Sponsor
- HOVON
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of clofarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoints: Feasibility of clofarabine with induction chemotherapy and Event-free survival. Planned start Jan 2010; status: not yet recruiting.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON22750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22750.